UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic diseases, announced the presentation of a poster reviewing the results of the Phase 1 Safety Study of its candidate drug, SBP-101, a polyamine metabolic inhibitor for pancreatic ductal adenocarcinoma (PDA) at PancreasFest in Pittsburgh, PA. PancreasFest is an international meeting of physicians and scientists committed to reporting and sharing research in pancreatic cancer and pancreatitis. The poster was presented by Michael Walker, M.D., Director of Pancreatic Research for Sun BioPharma.
Dr. Walker said, “The conclusion of the study was that SBP-101 was well tolerated at dose levels 1-4 and that a dose of 0.8 mg/kg of body weight exceeded the maximum tolerated dose (MTD). The best tumor response occurred with 0.2 mg/kg/day. The low incidence of adverse events below the MTD and absence of drug-related bone marrow toxicity or peripheral neuropathy in these heavily pre-treated PDA patients, suggest the potential for SBP-101 as an addition to front-line treatment for PDA and justify a combination study.”